DK1633327T3 - Fremgangsmåde til forbedring af stabilitet og opbevaringslevetid af liposomkomplekser - Google Patents
Fremgangsmåde til forbedring af stabilitet og opbevaringslevetid af liposomkomplekserInfo
- Publication number
- DK1633327T3 DK1633327T3 DK04754323.6T DK04754323T DK1633327T3 DK 1633327 T3 DK1633327 T3 DK 1633327T3 DK 04754323 T DK04754323 T DK 04754323T DK 1633327 T3 DK1633327 T3 DK 1633327T3
- Authority
- DK
- Denmark
- Prior art keywords
- storage life
- improving stability
- liposome complexes
- complex
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47550003P | 2003-06-04 | 2003-06-04 | |
PCT/US2004/017695 WO2005000271A1 (en) | 2003-06-04 | 2004-06-04 | Method for improving stability and shelf-life of liposome complexes |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1633327T3 true DK1633327T3 (da) | 2010-11-15 |
Family
ID=33551542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04754323.6T DK1633327T3 (da) | 2003-06-04 | 2004-06-04 | Fremgangsmåde til forbedring af stabilitet og opbevaringslevetid af liposomkomplekser |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050002998A1 (da) |
EP (1) | EP1633327B1 (da) |
JP (2) | JP4987474B2 (da) |
CN (2) | CN1798545B (da) |
AT (1) | ATE476964T1 (da) |
AU (1) | AU2004251680B2 (da) |
CA (1) | CA2528411C (da) |
DE (1) | DE602004028610D1 (da) |
DK (1) | DK1633327T3 (da) |
ES (1) | ES2350485T3 (da) |
HK (2) | HK1086202A1 (da) |
PL (1) | PL1633327T3 (da) |
PT (1) | PT1633327E (da) |
WO (1) | WO2005000271A1 (da) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8617514B2 (en) | 1999-02-22 | 2013-12-31 | Georgetown University | Tumor-targeted nanodelivery systems to improve early MRI detection of cancer |
US9034330B2 (en) * | 1999-02-22 | 2015-05-19 | Georgetown University | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof |
JP4571514B2 (ja) * | 2005-01-21 | 2010-10-27 | ポーラ化成工業株式会社 | ベシクル系外用組成物 |
NZ562946A (en) * | 2005-04-29 | 2011-08-26 | Univ Louisville Res Found | Cell-surface decoration with active agents |
KR20080064169A (ko) * | 2005-10-20 | 2008-07-08 | 조지타운 유니버시티 | 암의 초기 mri 검출을 개선하기 위한 종양-표적화나노전달 시스템 |
WO2007132873A1 (ja) * | 2006-05-17 | 2007-11-22 | Yoshiyuki Koyama | 核酸、オリゴ核酸、又はその誘導体導入用の凍結乾燥体 |
EP2111185B1 (en) | 2007-01-30 | 2017-12-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Bioerodible wraps and uses therefor |
WO2009009054A1 (en) | 2007-07-09 | 2009-01-15 | Georgetown University | Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery |
CN101485629B (zh) * | 2008-01-16 | 2013-01-23 | 沈阳药科大学 | 一种给药系统及其制备方法 |
US8591942B2 (en) | 2009-09-23 | 2013-11-26 | Indu JAVERI | Methods for the preparation of liposomes comprising docetaxel |
US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
US9622849B2 (en) | 2009-10-28 | 2017-04-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bioerodible wraps and uses therefor |
EP2519188A4 (en) | 2009-12-31 | 2017-03-22 | Neograft Technologies, Inc. | Graft devices and methods of fabrication |
EP2560637B1 (en) | 2010-04-06 | 2018-11-07 | Fred Hutchinson Cancer Research Center | Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells |
US9445874B2 (en) | 2010-07-19 | 2016-09-20 | Neograft Technologies, Inc. | Graft devices and methods of use |
WO2013016349A2 (en) | 2011-07-25 | 2013-01-31 | Neograft Technologies, Inc. | Vessel treatment methods and devices for use in a graft device |
CA2806896C (en) | 2012-09-19 | 2021-06-15 | Georgetown University | Targeted liposomes prepared by ethanol injection |
US20140120157A1 (en) | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
KR20150131263A (ko) | 2013-03-14 | 2015-11-24 | 조지타운 유니버시티 | 신경 작용제에 대한 노출을 위한 치료 |
WO2015077602A1 (en) | 2013-11-22 | 2015-05-28 | Fred Hutchinson Cancer Research Center | Methods for identifying therapeutic targets and treating and monitoring cancers |
EP3226875B1 (en) * | 2014-12-03 | 2020-05-27 | Capricor, Inc. | Processes for producing stable exosome formulations |
ES2862191T3 (es) * | 2015-07-22 | 2021-10-07 | Nitto Denko Corp | Composiciones y métodos para formas de liófilos de nanopartículas |
US10940112B2 (en) | 2016-05-04 | 2021-03-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
CN109562067A (zh) * | 2016-08-02 | 2019-04-02 | 库里尔克思股份有限公司 | 制备脂质体的方法 |
CN114344486A (zh) * | 2017-10-20 | 2022-04-15 | 生物技术公司 | 适用于治疗的脂质体rna制剂的制备和储存 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4857319A (en) * | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
JPH01106829A (ja) * | 1987-10-21 | 1989-04-24 | Tosoh Corp | スーパーオキサイドジスムターゼ保持リポソーム製剤の凍結乾燥法 |
WO1993020802A1 (en) * | 1992-04-09 | 1993-10-28 | Northwestern University | Acoustically reflective liposomes and methods to make and use the same |
WO1996040265A1 (en) * | 1995-06-07 | 1996-12-19 | The Regents Of The University Of California | Stabilization of polynucleotide complexes |
US5753262A (en) * | 1995-06-07 | 1998-05-19 | Aronex Pharmaceuticals, Inc. | Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof |
US5811406A (en) * | 1995-06-07 | 1998-09-22 | Regents Of The University Of California | Dry powder formulations of polynucleotide complexes |
ATE459340T1 (de) * | 1997-11-19 | 2010-03-15 | Univ Georgetown | Zielgerichtete liposomen zur verabreichung von genen |
EP1811036B8 (en) * | 1999-02-22 | 2011-09-21 | Georgetown University | Antibody fragment-targeted immunoliposomes for systemic gene delivery |
JP2001002592A (ja) * | 1999-06-18 | 2001-01-09 | Dai Ichi Seiyaku Co Ltd | 遺伝子導入用組成物 |
JP2001316297A (ja) * | 2000-02-23 | 2001-11-13 | Kaken Pharmaceut Co Ltd | 遺伝子包埋リポソーム製剤及びその製法 |
US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
-
2004
- 2004-06-04 AT AT04754323T patent/ATE476964T1/de not_active IP Right Cessation
- 2004-06-04 CN CN200480015495XA patent/CN1798545B/zh not_active Expired - Fee Related
- 2004-06-04 AU AU2004251680A patent/AU2004251680B2/en not_active Ceased
- 2004-06-04 JP JP2006515186A patent/JP4987474B2/ja not_active Expired - Fee Related
- 2004-06-04 DK DK04754323.6T patent/DK1633327T3/da active
- 2004-06-04 PL PL04754323T patent/PL1633327T3/pl unknown
- 2004-06-04 DE DE602004028610T patent/DE602004028610D1/de active Active
- 2004-06-04 EP EP04754323A patent/EP1633327B1/en not_active Not-in-force
- 2004-06-04 US US10/860,640 patent/US20050002998A1/en not_active Abandoned
- 2004-06-04 CN CN201310185765.2A patent/CN103251562B/zh not_active Expired - Fee Related
- 2004-06-04 CA CA2528411A patent/CA2528411C/en not_active Expired - Fee Related
- 2004-06-04 WO PCT/US2004/017695 patent/WO2005000271A1/en active Application Filing
- 2004-06-04 PT PT04754323T patent/PT1633327E/pt unknown
- 2004-06-04 ES ES04754323T patent/ES2350485T3/es active Active
-
2006
- 2006-08-02 HK HK06108605.4A patent/HK1086202A1/xx not_active IP Right Cessation
-
2011
- 2011-12-22 JP JP2011281918A patent/JP2012121885A/ja active Pending
-
2014
- 2014-02-14 HK HK14101408.8A patent/HK1188147A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2005000271A1 (en) | 2005-01-06 |
PL1633327T3 (pl) | 2011-02-28 |
CA2528411A1 (en) | 2005-01-06 |
CN103251562B (zh) | 2016-04-27 |
AU2004251680B2 (en) | 2010-02-18 |
CN1798545B (zh) | 2013-06-05 |
JP2012121885A (ja) | 2012-06-28 |
EP1633327A1 (en) | 2006-03-15 |
HK1188147A1 (zh) | 2014-04-25 |
PT1633327E (pt) | 2010-11-08 |
EP1633327B1 (en) | 2010-08-11 |
AU2004251680A1 (en) | 2005-01-06 |
CN103251562A (zh) | 2013-08-21 |
ATE476964T1 (de) | 2010-08-15 |
EP1633327A4 (en) | 2009-03-04 |
ES2350485T3 (es) | 2011-01-24 |
CA2528411C (en) | 2012-09-04 |
DE602004028610D1 (de) | 2010-09-23 |
JP2006526658A (ja) | 2006-11-24 |
JP4987474B2 (ja) | 2012-07-25 |
US20050002998A1 (en) | 2005-01-06 |
CN1798545A (zh) | 2006-07-05 |
HK1086202A1 (en) | 2006-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1633327T3 (da) | Fremgangsmåde til forbedring af stabilitet og opbevaringslevetid af liposomkomplekser | |
WO2007058776A3 (en) | Hepatocyte growth factor intron fusion proteins | |
DK1180121T3 (da) | Langtidsvirkende insulinotrope peptider | |
SE8504945L (sv) | Farmaceutiska kompositioner innehallande antracyklinglykosider | |
NO875299D0 (no) | Insulinpreparat for ikke-paranteral administrasjon. | |
DE10199011I2 (de) | ASP-B28-Insulinkristalle. | |
HU202761B (en) | Process for producing stabilized erythropoietin compositions | |
WO2001023421A3 (en) | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease | |
ATE217317T1 (de) | Triazolinthion-phosphorsäure-derivate | |
DK281184D0 (da) | Galeniske praeparatformer for orale antidiabetica og fremgangsmaade til deres fremstilling | |
BRPI0518636B8 (pt) | kits não-radioativo liofilizado de multi-doses, e, processo para a preparação de múltiplas doses de paciente unitárias do radiofarmacêutico tetrofosmina- 99m tc" | |
ATE251634T1 (de) | Chirale phosphorierte ligande brauchbar in katalysatoren | |
RU96119391A (ru) | Фармацевтический препарат, содержащий плазминогенактиваторы | |
DK1377164T3 (da) | Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo | |
MXPA03003125A (es) | Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos. | |
NO871599D0 (no) | Sammensetning for stimulering av kondrocytter og osteoblaster (osseinhydroksyapatittforbindelse), fremgangsmaate for fremstilling derav og farmasoeytiske preparater inneholdende sammensetningen. | |
WO2000070665A3 (en) | Long lasting anti-angiogenic peptides | |
CN103143000B (zh) | 一种重组人干扰素α2b制剂 | |
HUP0203195A2 (hu) | Redox reverzibilis HCV-fehérjék natívhoz hasonló konformációval | |
IT8619431A0 (it) | Composto farmacologicamente attivo e composizioni farmaceutiche che lo contengono, procedimento per prepararlo e intermedio utile in detto procedimento. | |
SUNAKAWA et al. | SUPERSELECTIVE RAPID INTRAARTERIAL INFUSION OF CARBOPLATIN PLUS RADIOTHERAPY FOR ORAL AND OROPHARYNGEAL CANCER | |
HUP0000552A2 (hu) | Egy O-(3-piperidino-2hidroxi-1-propil)-hidroximsav halogenidszármazék, annak alkalmazása, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény | |
RU2000104444A (ru) | Способ лечения больных с аменореей центрального генеза | |
RU99116894A (ru) | Способ профилактики пролиферативной витреоретинопатии | |
RU99107584A (ru) | Способ лечения увеитов у детей |